Alan Kramer, MD
Cardiovascular Disease · Voorhees, NJNPI 1316918956
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Atricure, Inc. at 47.2% of the total. Reporting peaked in 2023 at $133 and has fallen 77.9% since, to $29 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NJ, where the typical reported total is $2,633.
Across 8 payments — averaging $28.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Atricure, Inc.$107
- Boston Scientific$49
- Amgen$41
- Genentech USA, Inc.$29
What the payments were for
- Food & beverage$226100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Atricure, Inc. | 2 | $107 |
| Boston Scientific | 2 | $49 |
| Amgen | 3 | $41 |
| Genentech USA, Inc. | 1 | $29 |
How this compares
$226 in reported general payments places this provider in the 10th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 378 | $560,619 |
| XareltoRivaroxaban | 136 | $167,963 |
| Repatha SureclickEvolocumab | 193 | $158,484 |
| EntrestoSacubitril/Valsartan | 72 | $107,270 |
| Praluent PenAlirocumab | 79 | $51,321 |
| Repatha SyringeEvolocumab | 45 | $41,689 |
| VascepaIcosapent Ethyl | 50 | $41,623 |
| Atorvastatin Calcium | 1,533 | $18,661 |
| Ezetimibe | 621 | $17,876 |
| Icosapent Ethyl | 29 | $17,035 |
| Rosuvastatin Calcium | 954 | $16,864 |
| Metoprolol Succinate | 984 | $14,506 |
| Losartan Potassium | 806 | $9,463 |
| Amlodipine Besylate | 1,149 | $9,150 |
| Potassium Chloride | 264 | $5,757 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Voorhees
- Elias IliadisVoorhees$158K
- Joseph ParrilloVoorhees$58K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.